19 December 2024
SPL receives positive FDA feedback on DEP SN38 for PROC
12 December 2024
Appendix 3G
12 December 2024
Appendix 3Y
4 December 2024
DEP Presentation at Radiopharmaceuticals Summit
29 November 2024
Results of 2024 Reconvened Annual General Meeting
27 November 2024
AGM Notice of Reconvened Meeting
26 November 2024
Results of 2024 Annual General Meeting
26 November 2024
AGM Chair's address and CEO's presentation
24 November 2024
Bell Potter Healthcare Conference Presentation
21 November 2024
DEP SN38 Results Showcased at GI Cancer Conference
6 November 2024
Appendix 3Y
1 November 2024
Appendix 3G
31 October 2024
Quarterly Activities Report & Appendix 4C
29 October 2024
Australian Microcap Conference Presentation
28 October 2024
Notice of Annual General Meeting/Proxy Form
25 October 2024
Appendix 2A
24 October 2024
Appendix 3Y
18 October 2024
SPL7013 Nasal Spray Australia Update
3 October 2024
Appendix 3H
3 October 2024
Date of Annual General Meeting 2024

Investor Relations

For general questions about Starpharma Holdings Limited, please contact us at:

T: +61 3 8532 2700
E: investor.relations@starpharma.com

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.